Peru secures 23.1 million future coronavirus vaccine doses from Pfizer, COVAX - (NASDAQ via NewsPoints Desk)

  • Peru has secured enough COVID-19 vaccine to give nearly three-quarters of its population at least one dose when the immunization is available, as reported in NASDAQ.

  • The country reached agreements with Pfizer and the global vaccine distribution program COVAX for the provision of 23.1 million doses. Some vaccine regimes will require two doses.

  • The government said it had signed a binding agreement with Pfizer for the purchase of 9.9 million doses of its vaccine which is in testing.

  • An additional 13.2 million doses will be bought through COVAX, which is headed by the GAVI, the Vaccine Alliance, and the World Health Organization, and aimed at promoting equitable access.

  • Peru's health ministry added that it was negotiating with other vaccine developers, including Sinopharm and Sinovac Biotech, Moderna, Novovax, Johnson & Johnson, AstraZeneca and COVAXX, a unit of United Biomedical, as well as Russia's Gamaleya Institute, which developed the coronavirus vaccine candidate Sputnik V.

To read more NewsPoints articles, click here.